BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10408492)

  • 41. Oral contraceptives and venous thromboembolism: consensus conference statement.
    Dialogues in Contraception Consensus Conference (1995: Chicago)
    Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors for fatal venous thromboembolism in young women: a case-control study.
    Thorogood M; Mann J; Murphy M; Vessey M
    Int J Epidemiol; 1992 Feb; 21(1):48-52. PubMed ID: 1544757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 44. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
    Helmerhorst FM; Bloemenkamp KW; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1997 Jul; 78(1):327-33. PubMed ID: 9198174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Combined contraceptives and cardiovascular risk].
    Belaisch J; Hommais-loufrani B
    Contracept Fertil Sex (Paris); 1987 Dec; 15(12 Suppl):1-8. PubMed ID: 12315199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias.
    Realini JP; Encarnacion CE; Chintapalli KN; Rees CR
    J Am Board Fam Pract; 1997; 10(5):315-21. PubMed ID: 9297655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
    Lidegaard O
    BMJ; 1993 Apr; 306(6883):956-63. PubMed ID: 8490470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill.
    Black C; Kaye JA; Jick H
    Br J Clin Pharmacol; 2002 Jun; 53(6):637-40. PubMed ID: 12047488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.
    Suissa S; Spitzer WO; Rainville B; Cusson J; Lewis M; Heinemann L
    Hum Reprod; 2000 Apr; 15(4):817-21. PubMed ID: 10739826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral contraceptives and venous thromboembolism.
    Paul C
    N Z Med J; 1996 Nov; 109(1033):413-5. PubMed ID: 8941290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral contraceptives and venous thromboembolism. A case-control study.
    Lidegaard O; Edström B; Kreiner S
    Contraception; 1998 May; 57(5):291-301. PubMed ID: 9673836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
    Rekers H; Norpoth T; Michaels MA
    Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Coagulation and thrombosis with OC use: physiology and clinical relevance.
    Comp PC
    Dialogues Contracept; 1996; 5(1):1-3. PubMed ID: 12347721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rebuilding confidence in oral contraceptives: a new imperative in family planning.
    Spitzer WO
    Br J Clin Pharmacol; 1996 May; 41(5):359-63. PubMed ID: 8735675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Oral contraceptives: APF takes a position].
    Sex Planeam Fam; 1995; (7):17-8. PubMed ID: 12179267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.